Mereo BioPharma Group plc
MREO
←Back to Recent Filings
| Filing |
DATE |
FP |
FY |
End Date |
URL |
VIEW |
|
| 8-K |
11/10/2025 |
Q3 |
2025 |
9/30/2025 |
SEC |
view |
data |
| 10-Q |
11/10/2025 |
Q3 |
2025 |
9/30/2025 |
SEC |
view |
|
| 8-K |
8/12/2025 |
Q2 |
2025 |
6/30/2025 |
SEC |
view |
data |
| 10-Q |
8/12/2025 |
Q2 |
2025 |
6/30/2025 |
SEC |
view |
|
| 8-K |
5/13/2025 |
Q1 |
2025 |
3/31/2025 |
SEC |
view |
data |
| 10-Q |
5/13/2025 |
Q1 |
2025 |
3/31/2025 |
SEC |
view |
|
| 8-K |
3/26/2025 |
Q4 |
2024 |
12/31/2024 |
SEC |
view |
data |
| 10-K |
3/26/2025 |
Q4 |
2024 |
12/31/2024 |
SEC |
view |
|
| 8-K |
11/12/2024 |
Q3 |
2024 |
9/30/2024 |
SEC |
view |
data |
| 10-Q |
11/12/2024 |
Q3 |
2024 |
9/30/2024 |
SEC |
view |
|
| 8-K |
8/13/2024 |
Q2 |
2024 |
6/30/2024 |
SEC |
view |
data |
| 10-Q |
8/13/2024 |
Q2 |
2024 |
6/30/2024 |
SEC |
view |
|
| 8-K |
5/15/2024 |
Q1 |
2024 |
3/31/2024 |
SEC |
view |
data |
| 10-Q |
5/15/2024 |
Q1 |
2024 |
3/31/2024 |
SEC |
view |
|
| 8-K |
3/27/2024 |
Q4 |
2023 |
12/31/2023 |
SEC |
view |
data |
| 10-K |
3/27/2024 |
Q4 |
2023 |
12/31/2023 |
SEC |
view |
|
| WIREPR |
9/7/2023 |
Q2 |
2023 |
6/30/2023 |
WIRE |
view |
data |
| 6-K |
9/7/2023 |
Q2 |
2023 |
6/30/2023 |
SEC |
view |
|
| WIREPR |
3/28/2023 |
Q4 |
2022 |
12/31/2022 |
WIRE |
view |
data |
| 20-F |
3/28/2023 |
Q4 |
2022 |
12/31/2022 |
SEC |
view |
|
| 6-K |
11/2/2022 |
Q2 |
2022 |
6/30/2022 |
SEC |
view |
|
| WIREPR |
3/31/2022 |
Q4 |
2021 |
12/31/2021 |
WIRE |
view |
data |
| 20-F |
3/31/2022 |
Q4 |
2021 |
12/31/2021 |
SEC |
view |
|
| 6-K |
11/2/2021 |
Q2 |
2021 |
6/30/2021 |
SEC |
view |
|
| WIREPR |
3/31/2021 |
Q4 |
2020 |
12/31/2020 |
WIRE |
view |
data |
| 20-F |
3/31/2021 |
Q4 |
2020 |
12/31/2020 |
SEC |
view |
|
| WIREPR |
9/29/2020 |
Q2 |
2020 |
6/30/2020 |
WIRE |
view |
data |
| 6-K |
9/29/2020 |
Q2 |
2020 |
6/30/2020 |
SEC |
view |
|
| WIREPR |
6/16/2020 |
Q4 |
2019 |
12/31/2019 |
WIRE |
view |
data |
| 20-F |
6/15/2020 |
Q4 |
2019 |
12/31/2019 |
SEC |
view |
|
| WIREPR |
9/17/2019 |
Q2 |
2019 |
6/30/2019 |
WIRE |
view |
data |
| 20-F/A |
5/29/2019 |
Q4 |
2018 |
12/31/2018 |
SEC |
view |
|